Blog

Guru Sonpavde: Potentially practice-changing highlights from 2 key Phase III clinical trials

adventhealth.com

Oct 21, 2024, 19:19

Guru Sonpavde: Potentially practice-changing highlights from 2 key Phase III clinical trials

Guru Sonpavde shared a post on LinkedIn:

”ESMO24 bladder cancer potentially practice-changing highlights from 2 key Phase III clinical trials on Doximity: Pleased to comment on NIAGARA (Neoadjuvant Gemcitabine-Cisplatin +/- peri-operative durvalumab for muscle-invasive bladder cancer) and AMBASSADOR (Adjuvant pembrolizumab vs observation for muscle-invasive bladder cancer) trials from AdventHealth Central Florida Cancer Institute, Orlando, Florida.”

Read further.

Adjuvant pembrolizumab AdventHealth Central Florida Cancer Institute bladder cancer cancer clinical trials Doximity Durvalumab ESMO24 Guru Sonpavde OncoDaily Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage